Navigation Links
ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
Date:11/1/2007

cturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

-- The BioArchive(R) System, an automated cryogenic device, is used by

cord blood stem cell banks in more than 25 countries for

cryopreserving and archiving cord blood stem cell units for

transplant. GE Healthcare is the non-exclusive global distribution

partner for the BioArchive System.

-- AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary, automated

device and companion sterile blood processing disposable for

harvesting stem cells from cord blood in a closed system. GE

Healthcare is the exclusive global distribution partner for the AXP

AutoXpress Platform.

-- The CryoSeal(R) FS System, an automated device and companion sterile

blood processing disposable, is used to prepare fibrin sealants from

plasma in about an hour. We received FDA approval to market the

CryoSeal FS System in liver resection surgeries in July 2007. The

CryoSeal FS System has received the CE-Mark. From a marketing

perspective, the CE Mark is the European equivalent to an FDA

approval, in that it allows sales of the product throughout the

European community. Asahi Medical is the exclusive distributor for the

CryoSeal System in Japan and the Company markets through independent

distributors in Europe and South America.

-- The Thrombin Processing DeviceTM (TPD(TM)) is a sterile blood

processing disposable that prepares activated thrombin from a small

aliquot of plasma in less than 30 minutes. The CE-Marked TPD is

currently being marketed in Europe by Biomet, Inc., subsidiary Biomet

Biologics, Medtronic, Inc. and independent distributors.

This press release, including statemen
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Metavante Corp. will continue M&A activity
2. Lucigen Corp. enters global licensing agreement
3. CIO Leadership Series: Jane Durment, Marcus Corp.
4. Brady Corp. acquires Korean counterpart
5. Brady Corp. raises $137 million in public offering
6. Symphony Corp. and CareEvolution to partner
7. RedPrairie Corp. introduces new supply chain software
8. California investors acquire RedPrairie Corp.
9. Symphony Corp. moving into Fitchburg Technology Campus
10. Local group building Dane County economic development corp.
11. M & Is Metavante completes Brasfield Corp. acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... New spin-out from Cancer ... Innovation Capital and Johnson & Johnson Development Corporation  ... focused on harnessing the potential of circulating tumour ... treatment, today announced it has raised £4m in ... including Cambridge Innovation Capital and Johnson & Johnson ...
(Date:9/22/2014)... , September 22, 2014 ... the addition of the "Global Biotechnology Reagents ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents ... to a system to detect and examine another ... generally used in laboratories to prepare, collect, and ...
(Date:9/22/2014)... Manchester have generated a new star-shaped molecule made up of ... ever created. , Known as a ,Star of ... over a quarter of a century and the team,s findings ... , Consisting of two molecular triangles, entwined about each other ... tiny each triangle is 114 atoms in length around ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 This is ... of the M-Phenylenediamine (mPDA) industry in Global and ... industry, including definitions, applications and industry chain structure. Global ... with a focus on history, developments, trends and competitive ... and Chinese situation is also offered. , The report ...
Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 3
... /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) today reported ... ended May 31, 2008. All dollar amounts referenced,herein are ... 31, 2008, our cash and cash equivalents totaled $12.4 ... The net loss for the second quarter of 2008 ...
... of Coronary Artery Disease ... Patients in Real-World Setting, ABBOTT PARK, Ill., July ... post-approval study, with six,hospital centers already recruiting and enrolling patients just ... V(TM),Everolimus Eluting Coronary Stent System. The XIENCE V USA study will,evaluate ...
... 9 Abt Bio-Pharma Solutions, Inc.,(ABS), a ... and,strategic commercialization solutions, is pleased to announce ... business strategy, has been promoted to,Executive Director ... Susan Windham-Bannister, who has been appointed,President & ...
Cached Biology Technology:Vasogen Announces Second Quarter 2008 Results 2Vasogen Announces Second Quarter 2008 Results 3Vasogen Announces Second Quarter 2008 Results 4Vasogen Announces Second Quarter 2008 Results 5Vasogen Announces Second Quarter 2008 Results 6Vasogen Announces Second Quarter 2008 Results 7Vasogen Announces Second Quarter 2008 Results 8Vasogen Announces Second Quarter 2008 Results 9Vasogen Announces Second Quarter 2008 Results 10Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 2Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 4Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister 2Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister 3
(Date:9/22/2014)... Yale University researchers are studying a potential new ... respiratory disease in which scars develop in the lungs ... microRNA mimic, miR-29, which is delivered to lung tissue ... fibrosis, it reversed fibrosis after several days. , ... EMBO Molecular Medicine . , "The mimic, when ...
(Date:9/22/2014)... New Rochelle, NY, September 22, 2014Cassava, also known as ... high yields in areas of Africa, Asia, and Latin ... With the availability of novel enzymes and processes designed ... then be used to produce sweeteners such as glucose, ... alternative to corn, as described in a Review article ...
(Date:9/22/2014)... manufacture their own "antifreeze" proteins to survive in ... side effect, researchers report: The protein-bound ice crystals ... when temperatures warm. , The finding is ... Academy of Sciences . , "We discovered what ... evolution of antifreeze proteins in Antarctic notothenioid fishes," ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3
... for a boat ride or even taken a drink from the ... how valuable? That,s always been a tough question for policy makers ... societal needs that compromise it, such as the need to grow ... so has been greatly enhanced by a new policy-making framework developed ...
... that there are 1.7 million species of animals, plants ... be discovered. Unfortunately, as new species are found, many ... biodiversity. The more diversity there is in a population, ... is key to ecosystem resilience. Disease, destruction of ...
... and decisions to use "least toxic pesticides" and "pesticides ... decade, but according to three scientific organizations the ... Society (APS) and the Plant-Insect Ecosystems Section of the ... not the correct approaches to the pesticide component of ...
Cached Biology News:Study offers new tool for incorporating water impacts into policy decisions 2Persistence or extinction: Through a mathematical lens 2Persistence or extinction: Through a mathematical lens 3Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 2Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 3Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 4Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 5
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known maize ...
... an excellent choice for supporting hydrocarbon processing. In ... this one-channel workhorse can double sample throughput by ... You get all the capability and reliability you ... that has the same proven performance of Agilents ...
... system combines world-class performance hardware, Cerity Networked ... world-renowned support and columns, as well as ... that lets you reach uncompromising results and ... data. The Agilent 6820 GC system is ...
... the six short years since publication of ... Walkers widely acclaimed Protein Protocols Handbook, there ... protein biochemistry. In recognition of the level ... rapid evolution of new methodologies directed to ...
Biology Products: